Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AMED Inaugurated with Diverse Talents as Unit Heads
April 2, 2015
- MHLW Notifies of New Criteria for Orphan Drug Designation
April 2, 2015
- MHLW Notifications Prod Generic Use under High-Cost Healthcare Benefit System
April 2, 2015
- PMDA Sets Up New Unit to Promote Medical Database Project
April 1, 2015
- LDP Legislators Discuss Legal Regulation of Clinical Research
April 1, 2015
- MHLW to Invite Candidate Products for “Sakigake” Designation System
March 31, 2015
- MHLW Reiterates Caution on Skin Disorders for Lamictal: Safety Bulletin
March 31, 2015
- Otani, Ex-Number 2 at MHLW, Tapped as Aide to Chief of AMED
March 30, 2015
- PMDA Launches Consultation Services for Academia-Led Trials
March 30, 2015
- MHLW OKs 32 Products Including Sovaldi, Lenvima
March 27, 2015
- Nonpartisan Group Launched to Push Biosimilar Use, Lawmaker-Sponsored Bill Eyed
March 27, 2015
- Govt OKs AMED’s 5-Year Plan Articulating Support for 200 Drug Seed Development Projects
March 26, 2015
- Cabinet OKs NIBIO Director Yoneda as Chief of Merged Institute
March 25, 2015
- Ministry Requires Addition of Thrombocytopenia as Serious ADR to Januvia
March 25, 2015
- Lawmakers to Form Nonpartisan Group to Spur Biosimilar Use
March 24, 2015
- Kitasato Daiichi Sankyo Vaccine to Remain in State Vaccine Project
March 24, 2015
- PMDA Pledges Cooperation to Promote Commercialization of Seeds: Chief Executive
March 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for March 9 - 22
March 23, 2015
- MHLW OKs Pfizer’s Jzoloft for PTSD Indication, Other Drugs
March 23, 2015
- 196 “Designated Intractable Diseases” Likely to Be Eligible for Subsidies from July
March 20, 2015
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…